STOCK TITAN
  1. Home
  2. VRX

Valeant Pharmaceuticals International Stock Price, News & Analysis

VRX

Company Description

Valeant Pharmaceuticals International (NYSE: VRX) is a publicly traded company.

VRX stock has gained 35.3% over the past year.

This page provides a comprehensive overview of VRX stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
0.00%
0.00
Last updated:
+35.34%
Performance 1 year
$0.0
Market Cap
0.0
Shares outstanding

Valeant Pharmaceuticals International (VRX) stock. Over the past 12 months, the stock has gained 35.3%.

Latest News

View All
—

Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction

clinical trial
—

Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2020 Results And Provides 2021 Guidance

earnings
—

Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses To Be Presented At The Virtual Global Specialty Lens Symposium

—

Bausch + Lomb Introduces SimplifEYE™ IOL Delivery System For enVista® Toric And Monofocal Preloaded Intraocular Lenses

—

Salix To Present Data For Products Across Its Portfolio At The American College Of Gastroenterology 2020 Virtual Annual Meeting

conferences
—

Bausch Health Releases Annual Corporate Social Responsibility Report

Valeant Pharmaceuticals International has 8 recent news articles. Key topics include clinical trial, earnings, conferences. View all VRX news →

SEC Filings

View All

No SEC filings available for VRX.

Financial Highlights

View Full Financials
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months